Log in to search using one of your social media accounts:

 

Outcomes with DA-EPOCH-R in the Treatment of Aggressive B Cell Lymphoma
Dose-adjusted (DA)-EPOCH-R has been utilized in efforts to improve upon R-CHOP as the standard treatment of diffuse large B cell lymphoma (DLBCL). Front-line R-CHOP vs. DA-EPOCH-R in a randomized controlled trial resulted in no difference in clinical outcomes (CALGB/Alliance 50303, ASH 2016). However, DA-EPOCH-R may still be considered in high grade B cell lymphoma (HGBCL), MYC aberrant/ “double hit lymphoma” (DHL), primary mediastinal B cell lymphoma (PMBCL), B cell lymphoma unclassifiable with features intermediate between DLBCL and classical Hodgkin lymphoma (also known as gray zone lymphoma (GZL)), and HIV-...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Craig Boddy, Carlos Galvez, Barbara Pro, Angela Fought, Leo Gordon, Jane Winter, Shuo Ma, Reem Karmali, Jason Kaplan Source Type: research

Impact of Comorbidities on Outcome of Diffuse Large B Cell Lymphoma (DLBCL)
The presence of comorbidity has a great influence on decision-making in management of Hematological malignancies. Previous reports showed poor outcome in several types of solid and hematologic malignancies due to associated comorbidities. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Mostafa F. Mohammed Saleh, Shimaa Abdelallah, Youseria Abdel Rahman, Essam Edin Abdel Mohsen, Rania Bakry, Eman M. Nagiub Abdelsalam Source Type: research

Mantle Cell Lymphoma: The Far-Far Away Treatment Results in a Public Hospital In Brazil
Growing understand Mantle Cell (MCL) Lymphoma pathogenesis develop new drugs and increase its overall survival. We do not observe this increasing in Brazil ’s public health system because no access to these drugs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Sergio Brasil, Carolina Cola ço, Cristina Bortolheiro, Tomas Barrese, Renata Bacic, Roberto Paes, Rodolfo Cancado Source Type: research

BH3 Mimetics May Have Utility in T Cell Non-Hodgkin Lymphomas
T cell non-Hodgkin lymphomas (T-NHL) are a heterogeneous group of diseases. Most of the treatments used for T-NHL are extrapolated from the treatment of B cell lymphomas and do not take into account any unique biology of T-NHL. A handful of agents are FDA-approved for relapsed and refractory T-NHL, but these agents have response rates on the order of 20-30%. Thus, there is a need for effective, rational therapies in T-NHL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Elizabeth Brem, Raphael Koch, Rachael Clark, Thomas Kupper, David Weinstock, Anthony Letai Source Type: research

Age as a Potential Novel Prognostic Indicator in Primary Cutaneous B-Cell Lymphoma (PCBCL)
PCBCL is a group of rare lymphoproliferative disorders. Indolent subtypes include Primary Cutaneous Marginal Zone Lymphoma (PCMZL) and Primary Cutaneous Follicular Center Lymphoma (PCFCL). Primary Cutaneous Diffuse Large B -cell Lymphoma (PCDLBCL) is highly aggressive. The Cutaneous Lymphoma International Prognostic Index (CLIPI) can risk- stratify indolent subtypes, but it does not consider age. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Poorvi Desai, Magali Van den Bergh, Xiaohui Zhang, Hailing Zhang, Braydon Schaible, Zhenjun Ma, Lubomir Sokol Source Type: research

Castleman Disease: Do Environmental Variations Explain Differences in the Clinical Spectrum? A Single Institution Experience In Brazil
Castleman disease (CD) is a rare benign lymphoproliferative disease that mimics lymphoma. There are no standard treatments and no descriptions of epidemiology or regional variations despite the greater understanding of this disease complexity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: S érgio Brasil, Julia Leite, Tomas Barrese, Renata Palhares, Roberto Paes, Rodolfo Cançado Source Type: research

An Evidenced Based Approach through the Use of CLIPi Score Validation to Standardize Practice in Nursing for Patients Diagnosed with Mycosis Fungoides/Se źary Syndrome
CTCL, CLIPi score validation, standardized practice. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Christa Roe, Brett Estrada, Janice Bennett, Frank Glass, Rami Komrokji, Lubomir Sokol Source Type: research

Single-Center Experience of Post-Transplant Lymphoproliferative Disorder after Liver Transplantation Treated with Immunochemotherapy
Post-transplant lymphoproliferative disorder (PTLD) is one of the major complications following transplantation. Limited data is available in PTLD after liver transplant. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Juan Alderuccio, Alexandra Stefanovic, Daniel Dammrich, Jennifer Chapman, Francisco Vega, Andreas Tzakis, Izidore Lossos Source Type: research

Assessment of Bone Marrow Infiltration and Minimal Residual Disease by Multidimensional Flow Cytometry in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Multidimensional flow citometry (MFC) has not yet shown a high clinical value in patients with DLBCL, probably due to the phenotypic heterogeneity of these lymphomas. We have evaluated bone marrow (BM) infiltration of in patients with DLBCL using MFC. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: M ónica Baile, S. Barrena, J.M. Sancho, C. Grande, R. Fernández, A. Batlle, M.J. Peñarrubia, F.J. Peñalver, J.A. Hernández-Rivas, J.M. Guinea, J.J. Pérez, M.B. Vidriales, A. Martín Source Type: research

A Prognostic Score for Survival in Patients Older than 65 Years with Diffuse Large B Cell Lymphoma
Prognostic scores used to predict response and overall survival, as is the International Prognostic Index (IPI) or Revised-International Prognostic Index in non-Hodgkin lymphoma, included a limited number of patients older than 65 years, none assessed comorbilities. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Myrna Candelaria, Nancy Reynoso, Mayra Ponce, Rodrigo Castillo, Diana Nolasco, Olga Gutierrez, David Cant ú Source Type: research

PTLD: Clinical Characteristics and Outcomes in Argentina
Post-transplant lymphoproliferative disorders (PTLD) are an heterogeneous group of lymphoid proliferations occurring after solid organ or allogeneic HSCT. Diagnosis is challenging, requires expert pathologist and high clinical suspicion. Data from Latin America is lacking. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Fernando Warley, Federico Jauk, Victoria Otero, Maria Florencia Tisi Ba ña, Marina Bonanno, Dana Kohan, Hernan Garcia Rivello Source Type: research

Analysis Of CD30 Expression in Patients With Diffuse Large B-Cell Lymphoma Treated at a Brazilian Universtiy Hospital
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and includes a heterogeneous group of diseases, identified by their morphological, immunohistochemistry (IHC) and molecular aspects. The expression of the CD30 by IHC has been described as having a good prognosis and correlated with an increase in progression-free survival(PFS) and overall survival(OS). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Bruno Francisco Buzetti Spinelli, Caroline Bonamin dos Santos Sola, Melyssa Grignet Ribeiro, Ana Paula Percicote, Samir Kanaan Nabhan Source Type: research

R-DA-EPOCH in Aggressive CD 20 Positive B Cell Lymphomas: Real-World Experience
Dose adjusted EPOCH with rituximab (R-DA-EPOCH) has shown improved survival in clinical trials Burkitt ’s lymphoma (BL) and Primary mediastinal B cell lymphoma (PMBCL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Prasanth Ganesan, Harshvardhan Atreya, Venkatraman Radhakrishnan, Manikandan Dhanushkodi, Thanda Joshua, Krishnarathinam Kannan, Shirley Sundersingh, Triavdi Ganesan, Tenali Sagar Source Type: research

The Role of FLI1 in mRNA Splicing and rRNA Processing of Diffuse Large B Cell Lymphoma (DLBCL)
DLBCL is the commonest lymphoma, accounting for 30-40% of the cases, and a clinically aggressive lymphoma. A large portion of DLBCL patients can nowadays be cured with chemotherapeutic regimens, such as R-CHOP. However, approximately 30-40% of patients will present a refractory disease or will experience a relapse, indicating the need of better understanding the disorder for further therapeutic improvements. Our group has functionally characterized an 11q24.3 region that is recurrently gained in DLBCL determining an upregulation of the transcriptional factor FLI1 that occurs in up to 25% of patients (Bonetti, Testoni et al...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Giulio Sartori, Sara Napoli, Luciano Cascione, Valdemar Priebe, Andrea Rinaldi, Francesco Bertoni Source Type: research

Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) —An Interim Analysis
CTL019 is an investigational chimeric antigen receptor (CAR) T-cell therapy with a high rate of durable complete responses (CRs) and a manageable safety profile in a single-center trial in adult patients with R/R DLBCL. Results of a planned interim analysis of a single-arm, open-label, multicenter, global phase 2 trial of CTL019 in patients ≥18 y with R/R DLBCL (JULIET; NCT02445248) are reported. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Stephen Schuster, Michael R. Bishop, Constantine Tam, Edmund K. Waller, Peter Borchmann, Joseph McGuirk, Ulrich J äger, Samantha Jaglowski, Charalambos Andreadis, Jason Westin, Isabelle Fleury, Veronika Bachanova, Stephen Ronan Foley, P. Joy Ho, Stephan Source Type: research

Clinicolaboratory Characteristics of the t(14;19)(q32;q13)-Positive Splenic Marginal Zone Lymphoma
Splenic marginal zone lymphoma (SMZL) is a well recognized B-cell neoplasm. The most frequent cytogenetic findings are involvement of chromosomes 1, 3, 7(usually deleted in 7q) and 8. The t(14;19)(q32;q13) is a rare cytogenetic abnormality with bcl-3 rearrangement that has been reported in other B-cell lymphomas. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Hunan Julhakyan, Tatyana Obukhova, Valeriy Savchenko Source Type: research

hnRNPK as a Driver of Lymphomagenesis
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a multi-functional ssDNA and RNA binding protein that regulates a multitude of cellular programs involved in tumorigenesis. Accumulating biochemical data suggest hnRNP K may have oncogenic functions through its transcriptional and translational activities. While clinical data from solid tumors suggest a potential role for hnRNP K in some tumor types, its role in lymphoid malignancies has not been studied. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Prerna Malaney, Marisa Hornbaker, Miguel Gallardo, Xiaorui Zhang, Mark McArthur, Carlos Bueso-Ramos, Ken Young, Juaquin Martinez-Lopez, Sean Post Source Type: research

Myeloid Differentiation Factor 88 (MYD88) Gene Mutation in Diffuse Large B-Cell Lymphomas: Should it be Included in Routine?
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults, accounting for 35% –40% of all cases. NF-κB constitutive activation is the most important alteration found in ABC DLBCL. Some genes are inactivated by somatic mutations and deletions such as TNFAIP3 (30% of cases), others, such as CARD11 (10% of cases), CD79B and CD79A (∼20% of cases), and MYD88 L265P (6-30% of c ases) are activated mostly by somatic mutations. MYD88 mutations are usually described in DLCBL ABC subtype and extranodal disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Laura Fogliatto, Marines Barra, Yuri Strey, Paula Oliveira, Israel Bendit, Camila Bender, Kamila Grokoski, Tito Costa, Andrea Kramer, Claudia Bica Source Type: research

Defining Progression Free Survival After Multiple Lines of Therapy and Impact of Dynamic Changes in FLIPI for Multiply Relapsed Follicular Lymphoma in the Rituximab Era Treated at Memorial Sloan Kettering Cancer Center (MSKCC)
Despite improved outcomes, Follicular lymphoma (FL) requires multiple lines of therapy. Outcomes of multiply relapsed and observed patients have not been extensively evaluated. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Anna Alperovich, Connie Batlevi, Katy Smith, Zhitao Ying, Philip Caron, Pamela Drullinsky, John Gerecitano, Audrey Hamilton, Paul Hamlin, Steve Horwitz, Anita Kumar, Mathew Matasar, Alison Moskowitz, Craig Moskowitz, Ariela Noy, Maria Lia Palomba, Carol P Source Type: research

Regimen Intensification may Improve Outcomes in Patients With Higher Risk Human Immunodeficiency Virus (HIV) Related Aggressive B-Cell Lymphomas
Despite effective HIV antiretroviral therapy, there remains an increased incidence of HIV related B-cell Non-Hodgkin lymphomas (NHL). The introduction of antiviral therapy and effective chemotherapy has led to improved overall outcomes. Regimen intensification (RI) in HIV associated B-cell NHLs has shown prolonged survival in the rituximab era. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Emilie Wang, Joseph Clara, Samir Dalia, Bijal Shah, Celeste Bello, Paul Chervenick, Mohamed Kharfan-Dabaja, Lubomir Sokol, Eduardo Sotomayor, Rami Komrokji, Julio Chavez Source Type: research

Still a Role of Splenectomy as First-Line Therapy of Splenic Marginal Zone Lymphoma?
Splenic marginal zone lymphoma (SMZL) characterized with primary spleen involvement and indolent course. The performance of splenectomy still controversal. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Hunan Julhakyan, Aminat Magomedova, Sergey Kravchenko, Karen Danishyan, Eduard Gemdzian, Suren Karagulyan, Elena Gribanova, Valentina Dvyrnik, Andrey Vorobjev, Valeriy Savchenko Source Type: research

Association of Complex Karyotype with Inferior Survival in Mantle Cell Lymphoma is Independent of Specific Cytogenetic Abnormalities
Risk stratification of newly diagnosed patients with mantle cell lymphoma (MCL) is primarily based on the MCL international prognostic index (MIPI) and Ki67. Single-center studies have reported inferior outcomes in patients with a complex karyotype (CK), but this remains an area of controversy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: I. Brian Greenwell, Ashley D. Staton, Michael Lee, Jeffrey M. Switchenko, Joseph Maly, Kristie Blum, Natalie Grover, Stephanie Mathews, Steven Park, Max Gordon, Alexy Danilov, Timothy Fenske, Narendranath Epperla, Mehdi Hamadani, Christopher Flowers, Jona Source Type: research

Multicentre Study of HCV Status in Egyptian Patients with B-Cell Non-Hodgkin ’s Lymphoma with Assessment of Patients’ Immunological State
Hepatitis C Virus is both hepatotropic and lymphomatropic virus affecting more than 180 million individuals worldwide. Chronic hepatitis C infection is associated with several hematological manifestations such as monoclonal-gammopathy of uncertain significance (MGUS), mixed cryoglobulinemia (MC), and B-cell non-Hodgkin lymphoma (B – NHL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Rasha Magdy Source Type: research

Pharmacological B Cell Depletion by Anti-CD20 Antibody Induces Trabecular Bone Loss in Mice
Targeted B cell therapy by anti-CD20 antibody has revolutionized the treatment of B cell malignancies and autoimmune disorders . A growing body of evidence links B cell homeostasis to bone metabolism, including reports indicating severe bone loss in a murine transgenic model of mature B cell depletion. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Albert Kolomansky, Naamit Deshet-Unger, Alina Ostrovsky, Nathalie Ben-Califa, Sahar Hiram-Bab, Tamar Liron, Howard Oster, Moshe Mittelman, Yankel Gabet, Drorit Neumann Source Type: research

Upregulation of TET Activity with Ascorbic Acid Induces Epigenetic Modulation of Lymphoma Cells
The Ten Eleven Translocation (TET) enzymes have been found to be mutated in both diffuse large B-cell (DLBCL) and peripheral T-cell (PTCL) lymphomas resulting in DNA hypermethylation. Various important tumor suppressor genes, such as SMAD1 (part of TGF- β signaling), are under-expressed due to aberrantly methylated promoters or enhancers. Recent studies in embryonal stem cells showed that ascorbic acid (AA) is a cofactor for TET with a binding site at the catalytic domain, and enhances TET activity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Niraj Shenoy, Tushar Bhagat, Mary Stenson, Xiaosheng Wu, Amit Verma, Thomas Witzig Source Type: research

Does Red Distribution Width (RDW) have a Prognostic Role in Aggressive Non-Hodgkin Lymphoma?
Recent studies indicate that higher Red Distribution Width (RDW) at diagnosis in different lymphproliferative malignancies is associated with poor outcome related to a higher proinflammatory status and comorbidities. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Eman M. Nagiub Abdelsalam, Hanan Eltybe, Mostafa F. Mohammed Saleh Source Type: research

A Single Institutional Experience of 261 Patients with Large Granular Lymphocytic Leukemia
Large granular lymphocytic leukemia (LGLL) is a rare clonal lymphoproliferative disorder of post-thymic T-cell or natural killer (NK)-cell lineage associated with cytopenias, splenomegaly, autoimmune disorders, and recurrent mucocutaneous infections. Treatment is dictated by the presence of these manifestations and consists of immunosuppressive therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Magali Van den Bergh, Leidy Isenalumhe, Emilie Wang, Braydon Schaible, Zhenjun Ma, Ling Zhang, Lubomir Sokol Source Type: research

Frequency of Additional Malignancies in Patients with Large Granular Lymphocytic Leukemia (LGLL): A Single Institutional Experience
Large granular lymphocyte (LGL) disorders represent a spectrum of aberrant T-cell or natural killer cell lymphocytic proliferations. LGLL is classically associated with autoimmune conditions and bone marrow (BM) failure disorders. SM has been reported in association with LGLL in about 10%. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Leidy Isenalumhe, Magali Van den Bergh, Emilie Wang, Braydon Schaible, Zhenjun Ma, Ling Zhang, Lubomir Sokol Source Type: research

Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
New treatments with novel mechanisms of action are needed for patients with relapsed/refractory (R/R) DLBCL and FL. These tumor cells may depend on the histone methyltransferase EZH2 to perpetuate a less-differentiated state, and activating mutations may be oncogenic drivers. Tazemetostat, a potent, selective EZH2 inhibitor, shows antitumor activity in preclinical models and a phase 1 study in patients (pts) with mutated or wild-type (wt) EZH2 tumors. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Franck Morschhauser, Gilles Salles, Pamela McKay, Herv é Tilly, Anna Schmitt, John Gerecitano, Peter Johnson, Steven Le Gouill, Michael Dickinson, Christophe Fruchart, Thierry Lamy, Aristeidis Chaidos, Wojciech Jurczak, Stephen Opat, John Radford, Pier L Source Type: research

High-Risk Pregnancies Outcome in Women Treated With Low Molecular Heparin
Describing the incidence of some complications in high-risk pregnancies during which women were treated with Low Molecular Weight Heparin (LMWH) and their association with particular variables. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Georges Rameh, Fouad Kerbage, Elie Akoury, Anthony El Sabbagh, Mostapha Chaaban, Patrick Zaarour, Georges Chahine, Marcel Massoud Tags: Research Topics Source Type: research

A Novel High Throughput Process for Generation and Characterization of Chimeric Antigen Receptor (CAR) T Cells
T cells genetically engineered to express chimeric antigen receptors (CARs) bind to surface antigens via a single-chain variable fragment (scFv) and elicit potent anti-tumor activity. To our knowledge no rapid CAR development platforms exist to facilitate the high-throughput generation and characterization of novel CARs that allows comprehensive head-to-head comparisons and selection of the best CAR candidates for clinical development. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Sabarinath Venniyil Radhakrishnan, Adam Miles, Djordje Atanackovic, Tim Luetkens Source Type: research

Availability of Essential Medicines for Pediatric Oncology in Armenia
During recent decades substantial improvements has been documented in pediatric oncology and currently in high-income countries the survival of pediatric cancer is around 85%, however, the picture is totally different in low and middle income countries (LMIC), where around 80% of all pediatric cancer cases are documented: in LMIC pediatric cancer survival can range from 0 up to 50-60%. Among the others, one of the main challenges in LMIC is the availability of cancer medications. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Tamara Simonyan, Ruzanna Papyan, Lilit Sargsyan, Lusine Hakobyan, Varduhi Grigoryan, Hakob Topchyan, Arpina Azaryan, Armen Tananyan, Gevorg Tamamyan Source Type: research

CCR6, IL7R, FAS AND MAdCAM-1 Single Nucleotide Polymorphisms are Associated With Higher Incidence of Infections in Allogeneic Stem-Cell Transplant From a Related Donor After a Reduced Intensity Conditioning Regimen: A Multicenter Experience
Infection complications are important cause of morbidity and non-relapse mortality after allogeneic hematopoietic stem cell transplantation (allo-SCT), even in HLA-identical sibling donors. Although there are many studies associating single nucleotide polymorphisms (SNPs) and allo-SCT evolution, these are mainly related with graft versus host disease (GVHD) and/or transplant related mortality (TRM), with few focused on post-allo-SCT infections. This multicentric study analyzes the potential implication of SNPs with cytomegalovirus (CMV) reactivation and fungal infection (FI) development in allo-SCT with reduced intensity c...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Nerea Arratibel, Maria Garc ía-Alvarez, Oriana Lopez-Godino, Estefania Garcia-Guerrero, Oscar Ferre, Eduardo Rodriguez-Arboli, Albert Esquirol, Cristina Castilla, Rodrigo Martino, Luis Corchete, Inmaculada Heras, Jose Antonio Perez-Simon, Estefanía Pere Source Type: research

Ruxolitinib for Steroid-Refractory GVHD
Steroid-refractory GVHD (SR-GVHD) is associated with poor outcomes and high rates of morbidity and mortality, and second-line agents have failed to demonstrate significant efficacy. A novel JAK1/2 inhibitor, ruxolitinib, which has been approved for subsets of myelofibrosis and polycythemia vera, has emerged as a possible therapeutic option in patients with SR-GVHD. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Alexander Coltoff, Guido Lancman, Amir Steinberg Source Type: research

Tandem High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Brain Tumors
Central nervous system (CNS) tumors are the second most common pediatric malignancies with an about 25% 5-year overall survival rate in high-risk group. Children under 4 year have very bad prognosis. We tried to assess the effectiveness of tandem high-dose chemotherapy (HDCT) with autologous hematopoietic stem-cell transplantation (auto-HSCT) in this patient group. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Asmik Gevorgian, Elena Morozova, Ilya Kazantsev, Tatiana Iukhta, Svetlana Safonova, Yury Punanov, Ludmila Zubarovskaya, Olga Zheludkova, Boris Afanasyev Source Type: research

Distribution Chemotherapy Response Modulating Genetic Polymorphisms in Armenian Population
Primary chemotherapy drug resistance is a one of the major issues of medical hematology-oncology affecting about 20% of all patients. In Armenia, clinical data suggest that the rate of primary resistance depends on the disease and treatment type and varies in the range of 10-30%. One of the mechanisms of resistance is a drug inactivation mediated by metabolizing enzymes and it has been known that the variability of those genes contributes to the response to drugs and treatment efficacy. In Armenia a number of drugs are used for treatment acute and chronic hematology-oncological diseases, such as doxorubicin and vincristine...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Arsen Arakelyan, Yervand Hakobyan, Ani Melkonyan Source Type: research

Investigating the Mechanisms of Methotrexate Neurotoxicity in Patients With Childhood Leukemia and Long-Term Survivors
Adverse neurological events are common (4-20%) during treatment for pediatric acute lymphoblastic leukaemia (ALL) and include seizures, stroke like syndrome and leukoencephalopathy. In addition, chronic neurotoxicity is emerging as a worrying late effect of treatment with long-term survivors experiencing decreased executive function, processing speed and memory function. Survivors are also at increased risk of experiencing learning difficulties, social withdrawal issues and inattention hyperactivity disorders. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Victoria Forster, Jane Carr-Wilkinson, Deborah Tweddle, Sirintra Nakjang, Sanaa Choufani, Rosanna Weksberg, Frederik van Delft Source Type: research

Outcome of Neutropenic Fever in Hospitalized Cancer Patients During a One-Year Follow-up: A Single Center Experience
Febrile neutropenia is a relatively frequent event among cancer patients treated with chemotherapy. Since these patients lack the appropriate immunologic response, early recognition and empiric treatment is crucial. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Riwa Sakr, Marcel Massoud, Wafaa Greige, Nathalie Bteich, Layale Rached, Fadi Nasr, Elie Akoury, Fouad Kerbage, Georges Chahine Source Type: research

Development of a Prognostic System to Predict the Response to Treatment of Neutropenic Fever in Patients With Hematological Malignancies
Predicting the response to treatment for NF is critical in patients with hematological malignancy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Hamdy Zawam, Ahmad Selim, Rasha Salama, Nivin Hanna, Wael Edessa Source Type: research

Hematogones as a Prognostic Indicator in Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience
Allogenic hematopoietic stem cell transplantation (aHSCT) is the treatment of choice for young severe aplastic anemia (SAA). Hematogones (HGs), reflect regeneration of bonemarrow post-chemotherapy and post-HSCT;a biomarker to predict aHSCT outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Mai Aly, Douaa Sayed, Esam Elbeih, Rafaat Abdel Fattah, Refat Naseer, Reem Elagooz, Almetwaly M. Sultan, Nahla El-Sharkawy, Reda Z. Mahfouz Source Type: research

Allogeneic Hematopoietic Stem Cell Transplant in Elderly Patients Using Reduce Intensity Conditioning Regimen: A Single Centre Experience
Allogeneic stem cell transplantation (SCT) remains a cornerstone in the treatment strategy of most hematologic malignancies. Previously, age and comorbidities were considered limiting factors. With the introduction of reduced intensity conditioning regimens (RIC) and the understanding of donor immune function, allogeneic SCT in adults aged more than 60 years gained its place. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Riwa Sakr, Sylvain Pilorge, Stephane Debotton, Claude Chahine, Tereza Coman, David Ghez, Alina Danu, Micol Jean-Baptiste, Florence Pasquier, Vincent Ribrag, Christophe Willekens, Eric Solary, Jean-Henri Bourhis, Cristina Castilla-Llorente Source Type: research

Slow Lymphocyte Reconstitution After Autologous Stem Cell Transplantation is Associated with Increased Apoptosis Rate of CD8 Cells and Predicts Adverse Clinical Outcome
We noticed that in patients undergoing autologous stem cell transplantation (ASCT), the post-transplant lymphocyte counts fluctuated significantly during the first post-transplant weeks and wondered what is the clinical significance of this observation, and what dictates the lymphocyte counts overtime. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Uri Rozovski, Boris Tartakovsky, Shani Frank, Alexey Fourman, Eti Zigman-Hofman, Moshe Yeshurun, Svetlana Trestman, Ella Naparstek Source Type: research

Igvh Somatic Mutation Profile in Splenic Lymphomas: Opportunities for Differential Diagnosis
Splenic Lymphomas are rare diseases often misdiagnosed as hairy cell leukemia (HCL), splenic diffuse red pulp lymphoma (SDRPL) and splenic marginal zone lymphoma (SMZL). Criteria for differential diagnosis of these diseases are still controversial and require further elaboration. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Hunan Julhakyan, Bella Biderman, Lyubov Al-Radi, Igor Yakutik, Svetlana Korzhova, Alla Kovrigina, Andrey Sudarikov, Valeriy Savchenko Source Type: research

Eltrombopag and Cyclosporine as First-Line Therapy in Patients with Severe Acquired Aplastic Anemia: A Two-part, 5-year, Single-Arm, Multicenter, Open-label, Phase 2 Trial (SOAR)
Eltrombopag (EPAG), a thrombopoietin receptor agonist (TPO-RA), has shown promising results in severe aplastic anemia (SAA), as a single agent in immunosuppressive therapy (IST)-refractory patients and in treatment-na ïve patients when combined with horse antithymocyte globulin (hATG) and cyclosporine (CsA). hATG is unavailable in most parts of the world and is associated with increased toxicity, especially in patients aged>60 years. Moreover, ∼1/3rd of patients after ATG/CsA are considered refractory. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Phillip Scheinberg, Joan Maier, Ozlem Ocak Arikan, Carlo Finelli, Junho Jang Source Type: research

Sequential Regimen with Thiotepa, Cyclophosphamide, Etoposide, Fludarabine and Busulfan in Allogeneic Stem Cell Transplantation for the Treatment of Relapsed and Refractory Hematological Malignancies
Relapsed / refractory leukemia and lymphoma (R/R, L/L) patients have a very poor prognosis despite all the well-known therapeutic strategies. Sequential conditioning followed by allogeneic stem cell transplantation (allo-SCT) provides an efficient disease control in those high risk patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Haidar El Darsa, Radwan Massoud, Ammar Zahreddine, Ali Bazarbachi, Jean El-Cheikh Source Type: research

Repertoire of IgVH Genes in Splenic Marginal Zone Lymphoma Complicated with Autoimmune Hemolytic Anemia
Splenic marginal zone lymphoma (SMZL) is an indolent B-cell lymphoma frequently associated with monoclonal gammopathy and autoimmune disorders. Therefore, whereas it is well known that the prevalence of autoimmune hemolytic anemia (AIHA) is highest in the more advanced stages of the disease and may depend on the type of treatment administered. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Hunan Julhakyan, Bella Biderman, Nina Tsvetaeva, Lyubov Al-Radi, Tatyana Moiseeva, Tatyana Savenko, Elena Gribanova, Anait Melikyan, Andrey Sudarikov, Valeriy Savchenko Source Type: research

MGMT Promoter Methylation as an Epigenetic Biomarker for the Estimation of Chemosensitivity towards the Alkylating Agents Based Chemotherapies
The repair enzyme MGMT is recognized as having a provocative clinical relevance linked with cancerogenesis mechanisms and also with the chemosensitivity to particular oncological treatments including alkylating agents. Therefore, the analytical methods designed for the function of the gene encoding MGMT are actually developed in order to respond to specific needs, regarding diagnosis and predictive or prognostic approaches of treatments. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Natalia Cucu, V. Constantinescu, Lilia Matei, Mihaela Dragomir, Silvia Aposteanu, D. Coriu, Rodica Talmaci Source Type: research

The Opportunistic Pathogen Corynebacterium bovis Augments Leukemia Patient Derived Xenograft Engraftment: A Cautionary Tale
Chronic Myelomonocytic Leukemia (CMML) is a lethal hematopoietic malignancy with no available cell line, primary culture cells, or murine models that fully recapitulate the disease. We have recently reported that the NSG-S mouse model, which expresses human interleukin 3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF), and stem cell factor (SCF) uniquely support the hematopoietic engraftment of human Chronic Myelomonocytic Leukemia (CMML) resulting in a humanized model that fully recapitulates the human condition (REF). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Alexis Vedder, Emily Miedel, Natalie Ragland, Robert Engleman, Maria Balasis, Christopher Letson, Eric Padron Source Type: research

JC Virus and Progressive Multifocal Leukoencephalopathy After Haplo-Identical T-Cell Replete Transplantation with Post-Infusion Cyclophosphamide Recipient
Progressive multifocal leukoencephalopathy (PML), caused by reactivation of the John Cunningham virus (JCV), almost exclusively in immunocompromised patients, is a rare usually fatal disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Rana Salem, Radwan Massouud, Souha kanj Sharara, Manal Hamdan, Rida Salman, Ali Bazarbachi, Jean El Cheikh Source Type: research

Diagnostic and Therapeutic Limitations and Delayed Diagnosis of Pediatric Hematologic Malignancies in Armenia: A Single-Institution Report
There is a significant survival gap for pediatric hematologic malignancies between developed and developing countries, and various diagnostic and therapeutic limitations contribute for that. Diagnosis delay of pediatric malignancies is a challenge not only in developing, but also developed world, and the data on this topic is limited. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Liana Safaryan, Lilit Sargsyan, Lusine Hakobyan, Samvel Iskanyan, Armen Avagyan, Davit Zohrabyan, Lilit Harutyunyan, Samvel Bardakchyan, Sergey Mkhitaryan, Ruzanna Papyan, Jemma Arakelyan, Liana Avetisyan, Hovhannes Vardevanyan, Armen Tananyan, Gevorg Tam Source Type: research